- ￥1590 - 5500
- MedChemExpress(MCE)
- 美国
- HY-19837
- 2025年07月08日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 保存条件：
Powder: -20°C, 3 years. In solvent: -80°C, 6 months; -20°C, 1 month.
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
1478712-37-6
- 规格：
1 mg/5 mg/10 mg
| 规格： | 1 mg | 产品价格： | ￥1590.0 |
|---|---|---|---|
| 规格： | 5 mg | 产品价格： | ￥3500.0 |
| 规格： | 10 mg | 产品价格： | ￥5500.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
BMS-986120
CAS No. : 1478712-37-6
MCE 国际站：BMS-986120
产品活性：BMS-986120 是first-in-class、具有口服活性的蛋白酶激活受体 4 (PAR4) 的可逆拮抗剂，在人类和猴子血液中的 IC50 值分别为 9.5 nM 和 2.1 nM。BMS-986120 具有有效选择性的抗血小板作用。
研究领域：GPCR/G Protein
作用靶点：Protease Activated Receptor (PAR)
In Vitro: BMS-986120 has high binding affinity to PAR4 expressed on HEK293 cells and inhibition of PAR4-induced calcium mobilization with an IC50 of 0.56 nM.
In Vivo: In monkeys, BMS-986120 (1 mg/kg) does not inhibit PA induced by PAR1-AP, ADP and collagen, supporting selectivity. BMS-986120 (0.2, 0.5, 1 mg/kg) reduces TW by 35±5, 49±4, and 83±4%, respectively. Maximum KBT and MBT increases are only 2.2-fold and 1.8-fold, respectively.
相关产品：Clinical Compound Library Plus | Bioactive Compound Library Plus | GPCR/G Protein Compound Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Coagulation and Anti-coagulation Compound Library | Heterocyclic Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Highly Selective Inhibitors Library | Vorapaxar | TRAP-6 | AZ3451 | SLIGRL-NH2 | PAR-4 Agonist Peptide, amide TFA | Trypsin | 2-Furoyl-LIGRLO-amide | GB-88 | SCH79797 | Protease-Activated Receptor-2, amide | GB-110 hydrochloride | FSLLRY-NH2 TFA | Parmodulin 2 | AC-55541 | I-191 | PZ-128 | AZ8838 | ENMD-1068 hydrochloride | Atopaxar | TFLLR-NH2(TFA) | PAR-2-IN-1 | VKGILS-NH2 | PAR-4 Agonist Peptide, amide | Protease-Activated Receptor-4 | tcY-NH2 TFA | Protease-Activated Receptor-1, PAR-1 Agonist TFA | Protease-Activated Receptor-3 (PAR-3) (1-6), human TFA
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验药 Keytruda（MSD）获 FDA 批准，三个月后，Opdivo （BMS）获 FDA 批准（Opdivo 也将成为首个在中国大陆上市的 PD-1 单抗药）。2016 年 FDA 批准首个抗 PD-L1 的抗体药 Tecentrip（Roche）应用于肿瘤治疗（图 1）。图 1：PD-1/PD-L1 发展历程中的部分关键节点PD-1/PD-L1 工作机制是怎样的？PD-1/PD-L1 免疫检查点抑制剂在癌症研究中倍受瞩目，而恶性肿瘤的十大重要标志之一就是免疫检查点参与的免疫逃避。PD-1 与其配体 PD
Immunohistochemical Assays of Farnesyltransferase Inhibition in Patient Samples
time, three different FT inhibitors (FTIs), SCH66336, R115777, and BMS-214662, are undergoing clinical testing. Phase III studies with R115777 in pancreatic and colorectal cancer have completed accrual. Because the FTIs are among the first potential
Combined Chromatin Immunoprecipitation and Bisulfite Methylation Sequencing Analysis
immunoprecipitation (ChIP) with bisulfite methylation sequencing assays, so-called ChIP and bisulfite methylation sequencing (ChIP-BMS). This technique provides precise information of DNA methylation status at the selected DNA fragments precipitated by the antibodies
技术资料暂无技术资料 索取技术资料
